News & Updates

Treatment with upadacitinib (UPA) delivers clinical benefits to patients with prior Crohn’s disease (CD)-related surgeries, according to a study presented at AIBD 2023. Moreover, a maintenance dose of 30 mg once a day (QD) demonstrates greater efficacy.

Risankizumab outdoes ustekinumab in achieving endoscopic remission at week 24 in patients with moderate-to-severe Crohn’s disease (CD), as well as in other clinical, endoscopic, and quality of life (QoL) outcomes, as shown by the results of the phase IIIB SEQUENCE trial presented at AIBD 2023.

A study presented at AIBD 2023 provides strong evidence that histological remission may be achievable in patients with ulcerative colitis (UC).

Faecal microbiota transplantation (FMT) does not appear to have any significant effect on the cardiometabolic parameters of individuals with at least one cardiometabolic issue, according to the results of a systematic review and meta-analysis.

Exposure to ozanimod during early pregnancy does not appear to pose risks of adverse pregnancy outcomes and foetal health despite recommendations to avoid getting pregnant while receiving ozanimod and for 3 months after treatment discontinuation, according to a study.

Individuals who have undergone an appendectomy may be at heightened risk of Crohn’s disease, according to the results of a systematic review and meta-analysis.